Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 358

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 358
---
 |               1,279 |
| December 21, 2023                 |     | Registered Offering                                     |     |   485,391,200 |     |             – |     |             – |     |          0.0040 |     |               1,918 |
| At December 31, 2023              |     |                                                         |     | 1,189,577,722 |     |     1,000,001 |     | 4,063,321,418 |     |                 |     |                     |

| 10. | Related party transaction |

The Directors consider
there to be no related party transactions during the periods reported other than Directors Remuneration.

| 11. | Contingent liabilities |

The Company entered into an Arrangement
Agreement with Bioasis on December 13, 2022 as amended on December 18, 2022. Under the agreement the Company agreed to acquire the
entire issued share capital of Bioasis for consideration of, in aggregate, approximately C$7.4
million (c£4.4 million). The agreement was subject to shareholder approval. On January 23, 2023 at the General Meeting to
approve the Arrangement Agreement none of the special resolutions were passed and, accordingly, the acquisition of Bioasis did not
proceed. Under the agreement the Company agreed to reimburse Bioasis US$225,000
for expenses relating to the transaction should the Company’s shareholders not approve the transaction. On March 3, 2023 the
Company advised Bioasis that it would offset this liability against the $500,000 loan it advanced to them during December 2022 and
January 2023.

As at June 30,
2024 and December 31, 2023 the Company had a contingent liability of $225,000 in relation to this potential liability.

On September 19, 2024, the Company announced a
ratio change on its ADSs from one (1) ADS representing four hundred (400) ordinary shares, to the new ratio of one (1) ADS representing
ten thousand (10,000) ordinary shares (the "Ratio Change"). The effective date of the Ratio Change is expected to be October
4, 2024.

| F-18 |

| 12. | Events after the reporting date |

On July 22, 2024,
the Company utilised its capacity under its Registration Statement on Form F-3 to raise $5